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ABSTRACT
This study assessed the incidence of gastrointestinal colonisation by resistant Enterobacteriaceae among
hospitalised patients, and identiﬁed risk-factors for ceftazidime and oﬂoxacin resistance. A prospective
cohort study was performed in ﬁve wards in a French teaching hospital during a 2-year period. Patients
hospitalised for > 48 h were enrolled between 17 April 2000 and 30 April 2002. A rectal swab was taken
at admission, then once-weekly and ⁄ or on the day of discharge. In total, 933 patients were investigated
and 585 amoxycillin-resistant isolates were obtained. Resistance rates for ceftazidime and oﬂoxacin were
9.4% and 4.8%, respectively. Multivariate analysis indicated that previous hospitalisation (p < 0.004)
and exposure to amoxycillin–clavulanate (p < 0.003) and ceftriaxone (p < 0.002) were associated
signiﬁcantly with ceftazidime resistance. Hospitalisation in the urology ward (p < 0.02) and previous
exposure to ﬂuoroquinolones (p < 0.01) were the two independent risk-factors associated with oﬂoxacin
resistance. The results of the study conﬁrmed that antibiotic use selected resistant Enterobacteriaceae
from the gut ﬂora. Resistance was observed mostly in patients with previous antibiotic exposure and
previous hospitalisation in wards with a high antibiotic selection pressure.
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INTRODUCTION
The increasing emergence of antibiotic-resistant
bacteria has created an enormous challenge for
microbiologists, clinicians, epidemiologists and
infection control personnel. Despite the introduc-
tion of guidelines and improved medical educa-
tion, antibiotic-resistant pathogens are a frequent
cause of hospital-acquired infections, particularly
in intensive care unit (ICU) patients, and result in
prolonged hospital stays and increased antibiotic
use, morbidity, mortality and cost. In the early
1980s, transferable resistance to third-generation
cephalosporins was reported in Klebsiella spp.,
followed by the emergence of ceftazidime resist-
ance in Escherichia coli, Enterobacter cloacae and
Serratia marcescens [1–4]. Increasingly, ﬂuoroqui-
nolone (FQ) resistance has been reported among
Staphylococcus aureus and Pseudomonas aeruginosa
isolates, and also in Enterobacteriaceae [5–7]. At
the same time, numerous studies have documen-
ted the relationship between antibiotic use
and the emergence of antibiotic resistance, partic-
ularly in Esch. coli [8–10]. However, few studies
have assessed the impact of hospital stay and
antibiotic use on gastrointestinal colonisation
with resistant Enterobacteriaceae. To identify
more precisely the risk-factors associated with
resistance to ceftazidime and FQs in Enterobacte-
riaceae, a prospective study was conducted in ﬁve
wards of a French teaching hospital during a
2-year period.
MATERIALS AND METHODS
Patient population
Consecutive new admissions between 19 April 2000 and 22
March 2002 to ﬁve different wards of the 3200-bed Nantes
university hospital were included in this study in order to build
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ﬁve cohorts of c. 200 patients. The ﬁve wards were: a 40-bed
urology ward (1000 admissions annually; 6000 patient-days); a
23-bed medical ward (1500 admissions annually; 8500 patient-
days); an 80-bed physical medicine and rehabilitation (PMR)
ward (1000 admissions annually; 38 000 patient-days); a 20-bed
medical ICU (800 admissions annually; 6300 patient-days); and
a 12-bed surgical ICU (800 admissions annually; 4300 patient-
days). Of the 933 patients included in the study, 199 were from
the surgical ICU (19 April 2000 to 5 March 2001), 105 were from
the medical ICU (2 March to 23 June 2001), 212 were from the
urology ward (20 June to 6 October 2001), 218 were from the
medical ward (4 October to 5 January 2002), and 199 were from
the PMRward (3 December 2001 to 22March 2002). The records
of all 933 patients were reviewed for demographical and
clinical data, including patient age, gender, length of hospital
stay, medical history (e.g., diabetes, chronic respiratory disease,
cancer), administration of corticosteroids or cytotoxic agents,
admission to the hospital within the preceding 12 months,
transfer from another ward or hospital, surgery in the pre-
ceding month, number of invasive procedures, and adminis-
tration of oral or parenteral antimicrobial agents in the month
before admission or during hospitalisation.
Microbiological methods
All newly admitted patients had a rectal swab taken on
admission, but patients hospitalised for < 48 h were excluded
from the study. Patients hospitalised for > 48 h had a further
rectal swab taken on day 3, and then weekly until discharge.
The specimens were ﬁrst resuspended in 2 mL of distilled
water; 100 lL of this suspension was then inoculated on to
bromocresol purple agar supplemented with vancomycin
32 mg ⁄L and either amoxycillin 8 mg ⁄L, ceftazidime 8 mg ⁄L,
imipenem 8 mg ⁄L, or oﬂoxacin 2 mg ⁄L. Susceptibility to
amoxycillin, amoxycillin-clavulanate, ticarcillin, cefoxitin, ceft-
azidime, imipenem, oﬂoxacin, ciproﬂoxacin and tobramycin
was determined for isolates growing on these selective media,
according to the recommendations of the Antibiogram Com-
mittee of the French Society for Microbiology [11]. The isolates
were identiﬁed using conventional tests and the API 20E
system (bioMe´rieux, Marcy l’Etoile, France).
Statistical analysis
Data were analysed using the EPI INFO v.6.04d (CDC,
Atlanta, GA, USA) and SYSTAT v.7 (Systat, Richmond, CA,
USA) computer databases. The inﬂuence of qualitative varia-
bles on the resistance of Enterobacteriaceae to ceftazidime and
oﬂoxacin was assessed with crude ORs, calculated by the
Mantel–Haenszel chi-square test. Quantitative variables were
compared between two groups (resistant vs. susceptible) by
Student’s t-test. An unconditional logistic regression analysis
was performed, with signiﬁcance set at p < 0.10, as assessed by
univariate analysis, to control for all the confounding factors.
Variables were introduced into the multivariate analysis in a
stepwise manner to construct the ﬁnal model, with p < 0.05
considered signiﬁcant.
RESULTS
In total, 3713 swabs were analysed from the 933
patients included in the study. The mean number
(range) of specimens per patient was four (1–23) in
the medical ICU, three (1–16) in the surgical ICU,
three (1–6) in the urology ward, three (1–7) in the
medical ward, and seven (1–24) in the PMR ward.
Non-duplicate consecutive amoxycillin-resist-
ant isolates of Enterobacteriaceae were obtained
from 585 (62.7%) patients, comprising 338 (57.8%)
males and 247 (42.2%) females, with a mean age
of 61.7 years (range 15–96 years). Of these, 155
(26.5%) were hospitalised in themedical ward, 149
(25.5%) in the PMR ward, 133 (22.7%) in the
surgical ICU, 85 (14.5%) in the urology ward, and
63 (10.8%) in the medical ICU. Among the 585
amoxycillin-resistant Enterobacteriaceae, 226
(39%) were Esch. coli, 169 (28%) Klebsiella pneumo-
niae or Klebsiella oxytoca, 96 (17%) Ent. cloacae or
Enterobacter aerogenes, 43 (7%) Citrobacter koseri or
Citrobacter freundii, 25 (4%) Hafnia alvei, 11 (2%)
Proteus mirabilis or Proteus vulgaris, ten (2%)
Morganella morganii, and ﬁve (1%) S. marcescens.
The rates of resistance to the different antibiotics
tested are summarised in Table 1. Fifty-ﬁve (9.4%)
isolates were resistant to ceftazidime, with the
highest rates among Enterobacter spp.,M. morganii
and Citrobacter spp.; 28 (4.8%) isolates were resist-
ant to oﬂoxacin, with the highest rates among
Proteus spp., S. marcescens andM. morganii. Resist-
ance to tobramycin was < 2% (11 ⁄ 584). All isolates
were susceptible to imipenem.
The ceftazidime resistance rate upon admission
was 3.4% (20 ⁄ 585), rising to 5.6% (35 ⁄ 585) during
hospitalisation (p < 0.007). The acquired ceftazi-
dime resistance rate ranged from 4.0% (6 ⁄ 149) in
the PMR ward to 11.1% (7 ⁄ 63) in the medical ICU
(Table 2). The mean time of acquisition for
patients who were not colonised with a ceftazi-
dime-resistant isolate upon admission was 15 (3–
107) days, ranging from 6.4 days in the PMR
ward to 36.6 days in the medical ICU.
The oﬂoxacin resistance rate was 2.4% (14 ⁄ 585)
upon admission and remained stable during
hospitalisation (2.4%). The acquired oﬂoxacin
resistance rate ranged from 1.5% (2 ⁄ 133) in the
surgical ICU to 4.7% (4 ⁄ 85) in the urology ward
(Table 2). The mean time of acquisition was 11
(3–50) days, ranging from 6.1 days in the medical
ward to 17 days in the PMR ward.
Of 585 patients colonised with amoxycillin-
resistant Enterobacteriaceae, 119 had received
antibiotic treatment during the previous month,
consisting of amoxycillin–clavulanate in 52
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patients, a FQ in 23 patients, ceftriaxone in 20
patients, amoxycillin in ten patients, and other
antibiotics in 14 patients. The frequency of anti-
biotic exposure varied among hospital wards,
with the highest exposure to amoxycillin–clavul-
anate and ceftriaxone among patients hospitalised
in the surgical ICU, and the highest exposure to
FQs among patients hospitalised in the urology
ward (Fig. 1).
According to univariate analysis, ceftazidime
resistance was signiﬁcantly higher among
patients with invasive procedures (p < 0.01),
dialysis (p < 0.003), previous hospitalisation
(p < 0.03), and previous antibiotic exposure
(p < 0.02). Use of amoxycillin–clavulanate and
ceftriaxone was associated signiﬁcantly with ceft-
azidime resistance. The mean time of exposure for
patients with amoxycillin–clavulanate-resistant
and amoxycillin–clavulanate-susceptible isolates
(3.1 days vs. 2.8 days, respectively; p < 0.76) and
the mean daily dose (2360 mg vs. 2571 mg,
respectively; p < 0.54) did not differ signiﬁcantly.
Likewise, the mean time of exposure to ceftri-
axone (4.7 days vs. 2.1 days, respectively;
p < 0.10) and the mean daily dose (1166 mg vs.
1750 mg, respectively; p < 0.28) did not differ
signiﬁcantly between patients with resistant and
susceptible isolates. Multivariate analysis identi-
ﬁed previous hospitalisation (p < 0.04) and pre-
vious exposure to amoxycillin–clavulanate
(p < 0.03) and ceftriaxone (p < 0.002) as being
associated signiﬁcantly with ceftazidime resist-
ance (Table 3).
For oﬂoxacin, univariate analysis indicated that
hospitalisation in the urology ward (p < 0.01),
kidney transplant (p < 0.003), previous antibiotic
exposure (p < 0.002) and previous FQ use
(p < 0.0003) were associated signiﬁcantly with
resistance. The mean time of exposure to FQs did
not differ signiﬁcantly between patients with
resistant and susceptible isolates (8.3 days vs.
7.6 days, respectively; p < 0.79). According to
multivariate analysis, hospitalisation in the uro-
logy ward (p < 0.02) and previous FQ exposure
Table 1. Antibiotic resistance among amoxycillin-resistant isolates of Enterobacteriaceae from the gut ﬂora of hospitalised
patients
Bacteria
Rate (%) of resistance
AMC TIC CF FOX CAZ IPM OFX TOB
Escherichia coli (n = 226) 63.7 99.1 19.5 3.5 1.8 0 5.3 0.4
Klebsiella spp. (n = 169) 6.7 100 4.9 4.3 0.6 0 1.2 0.6
Enterobacter spp. (n = 96) 100 35.4 100 100 33.3 0 7.3 5.2
Citrobacter spp. (n = 43) 60.5 100 60.5 55.8 23.2 0 4.7 2.3
Hafnia alvei (n = 25) 100 4 100 0 20 0 0 0
Proteus spp. (n = 11) 16.7 41.7 25 0 0 0 33.3 8.3
Morganella morganii (n = 10) 100 20 100 80 30 0 10 0
Serratia marcescens (n = 5) 100 20 100 100 0 0 20 20
AMC, amoxycillin–clavulanate; TIC, ticarcillin; CF, cephalothin; FOX, cefoxitin; CAZ, ceftazidime; IPM, imipenem; OFX, oﬂoxacin; TOB, tobramycin.
Table 2. Ceftazidime and oﬂoxacin resistance among
amoxycillin-resistant isolates of Enterobacteriaceae isola-
ted from the gut ﬂora of hospitalised patients
No. of
patients
CAZ resistance
No. (%)
OFX resistance
No. (%)
On admission Acquired On admission Acquired
Surgical ICU 133 7 (5.3) 9 (6.8) 3 (2.3) 2 (1.5)
Medical ICU 63 1 (1.6) 7 (11.1) 0 (0) 0 (0)
Urology 85 1 (1.2) 6 (7.1) 5 (5.9) 4 (4.7)
Medicine 155 8 (5.2) 7 (4.5) 4 (2.6) 3 (1.9)
PMR 149 3 (2.0) 6 (4.0) 2 (1.3) 5 (3.4)
Total 585 20 (3.4) 35 (5.6) 14 (2.4) 14 (2.4)
CAZ, ceftazidime; OFX, oﬂoxacin; ICU, intensive care unit; PMR, physical medicine
and rehabilitation. 32
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Fig. 1. Proportion (%) of patients exposed to amoxycillin–
clavulanate (AMC), ceftriaxone (CRO) and ﬂuoroquino-
lone (FQ) treatment before admission. ICU, intensive care
unit; PMR, physical medicine and rehabilitation.
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(p < 0.01) were identiﬁed as independent risk-
factors associated with oﬂoxacin resistance
(Table 4).
DISCUSSION
Reported rates for antibiotic resistance in Entero-
bacteriaceae usually concern isolates responsible
for community- or hospital-acquired infections.
Moreover, studies tend to focus on urinary tract
infections and assess the resistance rates in
Esch. coli, which is the most common pathogen
involved in these infections [7]. This could explain
why percentages of resistance may differ within
or among monitored geographical areas or
countries [10,12]. In a recent study, Sader et al.
[13] tested a total of 48 440 isolates of Enterobac-
teriaceae from patients hospitalised at sites
participating in the SENTRY antimicrobial sur-
veillance programme in four international regions
between 1997 and 2001, including different sites
of infection. Esch. coli was the pathogen isolated
most frequently (46.1%), followed by Klebsiella
spp. (21.3%) and Enterobacter spp. (12.2%). The
ceftazidime and FQ resistance rates among
the isolates were 8.6% and 9.5%, respectively.
The present study showed that the frequency
of the different organisms and rates of resistance
to ceftazidime (9.4%) did not differ signiﬁcantly
among isolates from gut ﬂora, even though the
study focused on amoxycillin-resistant isolates.
Half of the species investigated in the present
study were naturally resistant to amoxycillin.
Ceftazidime resistance occurred essentially
among Enterobacter spp., Citrobacter spp., and
Morganella spp., all of which produce an inducible
AmpC cephalosporinase that can become consti-
tutively derepressed. Ceftazidime resistance was
either absent or rare in Proteus spp., Klebsiella spp.,
and Esch. coli, which do not possess an inducible
cephalosporinase.
The lower incidence of oﬂoxacin resistance
observed in the present study, compared with
data from the SENTRY programme, could be
explained by the study design. Effectively, all
isolates of Esch. coli susceptible to amoxycillin
were excluded from the analysis. Some of those
isolates were probably resistant to oﬂoxacin, as
studies performed between 1995 and 1999
showed that trends toward resistance to FQs
among Esch. coli isolates have increased steadily
since the introduction of FQs [5,13–15]. Recently,
Viray et al. [16] showed that the prevalence of
antimicrobial resistance has increased signiﬁ-
cantly in long-term-care facilities, despite sub-
stantial variations among institutions, and that
these trends are particularly pronounced for FQ
resistance among Enterobacteriaceae.
Such ﬁndings indicate that antibiotic resistance
is widespread, highlighting the need for future
studies to elucidate more clearly the risk-factors
for emerging resistance. Numerous studies have
documented the relationship between antibiotic
use and the emergence of antibiotic resistance in
clinical isolates. The most effective approach to
prevent the transmission of resistant pathogens is
to prevent the initial emergence of resistance in
the gut ﬂora, through selected and appropriate
use of antibiotics [17–21].
To assess the role of antibiotic use and length of
hospital stay on the gut ﬂora, the present study
focused on ceftazidime and oﬂoxacin resistance
among patients hospitalised in ﬁve wards.
According to multivariate analysis, previous
exposure to amoxycillin–clavulanate (OR 2.39)
and ceftriaxone (OR 5.61) were independent
risk-factors associated with gastrointestinal colo-
nisation by ceftazidime-resistant Enterobacteria-
ceae. Moreover, higher ceftazidime resistance
rates were observed in hospital areas with the
highest proportion of patients who had been
Table 3. Multivariate analysisa of independent risk-factors
for gastrointestinal colonisation by ceftazidime-resistant
Enterobacteriaceae
Risk-factor Estimate OR 95% CI p
Constant ) 3.119 – –
No. (> 2) of invasive procedures 0.824 2.28 0.67–7.67 0.18
Dialysis 0.721 1.63 0.51–3.42 0.34
Previous (1 month) antibiotic use 0.012 1.01 0.43–2.35 0.97
Previous (1 year) hospitalisation 0.697 2.01 1.04–3.85 0.04
Previous (1 month) exposure to AMC 0.872 2.39 1.06–5.38 0.03
Previous (1 month) exposure to CRO 1.725 5.61 1.91–16.41 0.002
aCalibration of the model (Hosmer–Lemeshow test; p < 0.587).
AMC, amoxycillin–clavulanate; CRO, ceftriaxone.
Table 4. Multivariate analysisa of independent risk-factors
for gastrointestinal colonisation by oﬂaxacin-resistant iso-
lates of Enterobacteriaceae
Risk-factor Estimate OR 95% CI p
Constant ) 3.566 – –
Previous (1 year) hospitalisation 0.388 1.47 0.61–3.57 0.39
Previous (1 month) antibiotic use 0.645 1.91 0.63–5.71 0.25
Hospitalisation in urology ward 1.603 2.24 1.09–10.57 0.02
Previous (1 month) exposure to FQ 1.702 5.48 1.45–20.81 0.01
aCalibration of the model (Hosmer–Lemeshow test; p < 0.408).
FQ, ﬂuoroquinolone.
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exposed to previous treatment with amoxycillin–
clavulanate and ceftriaxone (i.e., ICUs). More than
one-third of patients were colonised by ceftazi-
dime-resistant Enterobacteriaceae at admission,
and ICU practitioners should use standardised
methods for evaluating antibiotic use and optim-
ising empirical and therapeutic use of amoxycil-
lin–clavulanate and ceftriaxone, particularly in
patients with previous hospitalisation during the
preceding year (OR 2.01). For oﬂoxacin resistance,
as described previously for clinical isolates [8], a
strong association was found between previous
oﬂoxacin exposure and gastrointestinal colonisa-
tion with oﬂoxacin-resistant Enterobacteriaceae
(OR 5.48), especially for patients hospitalised in
the urology ward. Although a signiﬁcant differ-
ence was not demonstrated, the dose and dur-
ation of treatment probably had a role in the
emergence of both ceftazidime and oﬂoxacin
resistance. Mahamat et al. [22] investigated long-
term trends in antibiotic resistance among
Esch. coli urinary tract isolates collected between
1997 and 2003, and found that increased use of
one deﬁned daily dose ⁄ 1000 patient-days of
oﬂoxacin, ciproﬂoxacin and norﬂoxacin induced
average increases of 0.81%, 0.65% and 0.53%,
respectively, in the overall level of oﬂoxacin
resistance among Esch. coli (p < 0.01), with aver-
age delays of 4, 4 and 6 months, respectively.
In conclusion, the results of the present study
show that antibiotic use selects resistance in
Enterobacteriaceae isolated from gut ﬂora. Resist-
ance is not apparent without systematic screening
for colonisation. Patients at particular risk are
those with previous antibiotic exposure or previ-
ous hospitalisation in wards with a high antibiotic
selection pressure. Preventing the emergence of
resistant microorganisms through the control of
antibiotic use is a complex problem. Careful
interpretation of analyses of risk-factors associ-
ated with colonisation by resistant strains, accord-
ing to the population and hospital area, should
help to educate clinicians concerning the problem
of antibiotic resistance and improve empirical
therapy with the aim of controlling the evolution
of resistance.
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